Headline
The latest stories from AHA Today.
The Centers for Medicare & Medicaid Services and Department of the Treasury approved a Section 1332 waiver for New Hampshire to implement a five-year reinsurance program for its individual health insurance market beginning in 2021.
Missouri voters approved an expansion of the state鈥檚 Medicaid initiative, the second state to do so during the COVID-19 pandemic.
Health care facilities or providers facing inadequate supplies of certain drugs needed to treat patients with COVID-19 should not use the products more than four hours beyond the labeled 鈥渋n-use time鈥 for refrigerated storage or two hours beyond the labeled 鈥渋n-use time鈥 for room temperature鈥
The departments of Health and Human Services and Defense will pay Janssen Pharmaceutical Companies of Johnson & Johnson $1 billion to manufacture 100 million doses of its COVID-19 vaccine candidate for use in clinical trials, or to vaccinate Americans if authorized by the Food and Drug鈥
The Centers for Medicare & Medicaid Services Aug. 4 released a proposed rule that would retroactively incorporate Medicare Advantage days into the Medicare fraction of a hospital鈥檚 disproportionate patient percentage for the Medicare Disproportionate Share Hospital program.
The Centers for Medicare & Medicaid Services Aug. 3 issued a proposed rule that would update physician fee schedule payments for calendar year 2021.
The Centers for Medicare & Medicaid Services released the calendar year 2021 outpatient prospective payment system/ambulatory surgical center proposed rule.
Health care providers should know the symptoms of acute flaccid myelitis and immediately hospitalize those who exhibit them, the Centers for Disease Control said.
A series of free videos from Med Tac offers guidance on how essential workers and the public can stay safe during the COVID-19 public health emergency.
The AHA, American Medical Association, American Society of Health-System Pharmacists, and United States Pharmacopeia convened a virtual summit to examine the resilience of the U.S. pharmaceutical supply chain in light of the current state of global pharmaceutical manufacturing.